scholarly journals METABOLIC AND ADIPOCYTOKINE PRECONDITIONS FOR PROGRESSION OF NON-ALCOHOLIC STEATOHEPATITIS IN OBESITY PATIENTS DUE TO COMORBIDITY WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE

2020 ◽  
Vol 1 ◽  
pp. 28-35
Author(s):  
Olha Hryniuk ◽  
Oksana Khukhlina ◽  
Oksana Liakhovych ◽  
Viktoriia Hutsuliak ◽  
Snizhana Hnatkovych
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Total Cholesterol ◽  
Pulmonary Disease ◽  
Liver Steatosis ◽  
Blood Lipid ◽  
Atherogenic Index ◽  
High Density Lipoproteins ◽  
Chronic Obstructive ◽  
Lung Pathology ◽  
Obstructive Pulmonary Disease

The increasing prevalence of chronic obstructive pulmonary disease (COPD) and nonalcoholic steatohepatitis (NASH) is a problem of high importance. Objective: to determine the state of blood lipid spectrum, glycemia, the degree of insulin resistance and their regulation by adipose tissue hormones in NASH patients against the background of obesity, depending on comorbidity with COPD. Methods. 130 patients were examined, including 35 NASH patients with obesity of the 1st stage (1 group), 60 NASH patients with obesity of the 1st stage and COPD 2-3 D (group 2), and 35 patients with COPD 2-3 D (group 3). Results: Blood lipid concentration in patients of the 1st and the 2nd groups exceeded the norm by 29.5% and 39.8% respectively (p<0.05). In the 3rd group - by 14.9% (p<0.05). The content of total cholesterol in the blood also points out its probable increase by 36.3%, 45.7% and 14.9% (p<0.05) in comparison with practically healthy individuals (PHI) in patients of the 1st, 2nd and 3rd groups. A probable increase in the concentration of triacylglycerols (TG) in blood (1.9 and 2.2 times, respectively (p<0.05)) was recorded in the 1st and 2nd groups of patients, while in patients of the 3rd group the changes were quite significant (1.6 times increase, p<0.05). Conclusions. Comorbidity of COPD in obese patients and NASH is an additional, powerful-inducing factor of lipid distress syndrome with significantly higher increase (compared with NASH without lung pathology) TG in blood, which form the basis of liver steatosis, total cholesterol, low density lipoproteins, with significantly higher decrease high density lipoproteins,  the atherogenic index, which are accompanied by hyperleptinemia, adiponectin deficiency, correlate with the degree of liver steatosis, fibrosis index, cytolytic activity, cholestatic, mesenchymal-inflammatory syndromes and are interrelated with hyperleptinemia, hypoadiponectinemia.

scholarly journals Lipid Profile Status of Chronic Obstructive Pulmonary Disease in Hospitalized Patients

2013 ◽  
Vol 3 (2) ◽  
pp. 42-45 ◽  
Author(s):  
K Begum ◽  
MK Begum ◽  
ZH Sarker ◽  
MRK Dewan ◽  
MJH Siddique
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Total Cholesterol ◽  
Pulmonary Disease ◽  
Mean Value ◽  
High Density Lipoproteins ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Healthy Control ◽  
The Mean

The aim of this study was to evaluate the serum level of total cholesterol, triglycerides (TG), low density lipoproteins (LDL) and high density lipoproteins, (HDL) in chronic obstructive pulmonary disease (COPD) patients admitted in National Institute of Disease of Chest and Hospital, Mohakhali, Dhaka during. January 2009 to January 2010. Twenty two patients with COPD and 22 healthy controls were included in this study. Total cholesterol, HDL and TG levels were determined with ILAB 1800 Chemistry Analyzer using ILAB test Reagents. LDL concentration was calculated using the Friedewald Equation. The mean level of TG was 150.04±29.66 mg/dl and 126.14±13.28 in COPD patients and healthy control, respectively. A statistically significant difference was found between the two groups (p<0.001). The mean level of TC was 181.83±20.11 mg/dl and 176.28±15.35 mg/dl in COPD patients and healthy control respectively (p<0.001). LDL level mean value was 116.12±14.26 mg/dl and 108.95±10.39 in COPD patients and control respectively (p<0.001). The mean value of HDL showed 38.79±2.4 in COPD patients and 39.014±1.56 in control. A statistically significance was also found between the two groups (p<0.001). Our results showed that the values of TC, TG, LDL were higher than healthy control that is highly significant statistically. On the other hand, the was significantly decreased HDL level compared with controls. DOI: http://dx.doi.org/10.3329/bjmb.v3i2.13810 Bangladesh J Med Biochem 2010; 3(2): 42-45

Clinical efficacy of hepatoprotector in the complex therapy of non-alcoholic steatohepatitis against the background of obesity for comorbidity with chronic obstructive pulmonary disease

2021 ◽  
Author(s):  
O. S. Khukhlina ◽  
O. Ye. Hryniuk
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Liver Steatosis ◽  
Subjective Assessment ◽  
Main Group ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Alcoholic Steatohepatitis ◽  
Complex Therapy

Objective — to establish the Antral efficacy in terms its effects on the intensity of clinical and biochemical syndromes of non‑alcoholic steatohepatitis (NASH) against the background of obesity at comorbidity with chronic obstructive pulmonary disease (COPD). Materials and methods. The examinations involved 65 NASH patients with I degree obesity and COPD 2 — 3 D. The patients were divided into two groups: 32 patients control groups received NASH therapy (Essentiale forte N (Sanofi Avensis/Nutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day) for 30 days and basic COPD therapy. The second, main group consisted of 33 NASH patients with I degree obesity and COPD 2 — 3 D, who along with the basic therapy for COPD received hepatoprotector Antral (Farmak, Ukraine) 200 mg, 3 times daily for 30 days. The mean age of the patients was 56.3 ± 3.21 years. The comparison group consisted of 30 apparently healthy people (AHP). The values of 30 practically healthy individuals were used as reference. Results. According to the scale of subjective assessment of the intensity of asthenia after treatment in patients of the main group, the effectiveness of its elimination was 3.9 times higher than that of patients in the control group (relative risk 3.87; 95 % CI [1.16 — 12.91], p < 0.05). The manifestations of dyspepsia disappeared faster in the patients of the main group. The use of antral 3.7 times more influenced the manifestations of cholestasis (p < 0.05). Body mass index (BMI) > 32 kg/m2 after treatment, which included a hypocaloric diet and Antral, remained in 13 patients in the main group (39.4 %) versus 29 patients in control group (90.6 %) (p < 0.05). During one month after the treatment, markers of cytolysis remained in 9 patients in control group (28.1 %), and in 1 patient of the main group (3.0 %) (OR 9.28; 95 % CI [1.11 — 77, 52], p < 0.05). The increased activity of cholestasis markers after treatment remained only in 5 patients in the main group (15.2 %) in comparison with 22 (68.8 %) controls. In the dynamics of treatment of patients in the main group, significant increase in the protein‑synthesizing function of the liver was revealed (albumin levels increased by 30.56 % (p < 0.05) relative to the indicator in the control group). Conclusions. The use of Antral in the complex therapy of NASH of patients with the concomitant obesity and COPD was more effective than standard therapy in terms of removal of clinical NASH syndromes: asthenic‑vegetative, dyspepsia, abdominal discomfort, cholestasis, hepatomegaly, degree of liver steatosis; biochemical syndromes: cytolysis, cholestasis, mesenchymal inflammation, hepatocellular failure.  

scholarly journals The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology

2018 ◽  
Vol 2018 ◽  
pp. 1-22 ◽  
Author(s):  
Marta Stolarczyk ◽  
Bob J. Scholte
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Cystic Fibrosis ◽  
Pulmonary Disease ◽  
Molecular Mechanisms ◽  
Egf Receptor ◽  
Airway Epithelial Cells ◽  
Chronic Obstructive ◽  
Lung Pathology ◽  
Obstructive Pulmonary Disease ◽  
Proinflammatory Mediators

Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) share molecular mechanisms that cause the pathological symptoms they have in common. Here, we review evidence suggesting that hyperactivity of the EGFR/ADAM17 axis plays a role in the development of chronic lung disease in both CF and COPD. The ubiquitous transmembrane protease A disintegrin and metalloprotease 17 (ADAM17) forms a functional unit with the EGF receptor (EGFR), in a feedback loop interaction labeled the ADAM17/EGFR axis. In airway epithelial cells, ADAM17 sheds multiple soluble signaling proteins by proteolysis, including EGFR ligands such as amphiregulin (AREG), and proinflammatory mediators such as the interleukin 6 coreceptor (IL-6R). This activity can be enhanced by injury, toxins, and receptor-mediated external triggers. In addition to intracellular kinases, the extracellular glutathione-dependent redox potential controls ADAM17 shedding. Thus, the epithelial ADAM17/EGFR axis serves as a receptor of incoming luminal stress signals, relaying these to neighboring and underlying cells, which plays an important role in the resolution of lung injury and inflammation. We review evidence that congenital CFTR deficiency in CF and reduced CFTR activity in chronic COPD may cause enhanced ADAM17/EGFR signaling through a defect in glutathione secretion. In future studies, these complex interactions and the options for pharmaceutical interventions will be further investigated.

scholarly journals Pulmonary infection with Mycobacterium szulgai: A case report

2019 ◽  
Vol 7 ◽  
pp. 2050313X1882344 ◽  
Author(s):  
Rex David S Gido ◽  
Amy L Wojciechowski ◽  
Rajinder PS Bajwa
Keyword(s):  
Risk Factors ◽  
Chronic Obstructive Pulmonary Disease ◽  
Case Report ◽  
Pulmonary Disease ◽  
Pulmonary Infection ◽  
Chronic Obstructive ◽  
Lung Pathology ◽  
Obstructive Pulmonary Disease

Mycobacterium szulgai is a non-tuberculous mycobacterium that is an uncommon cause of infection in humans. Risk factors for infection include immunosuppression and pre-existing lung pathology. Herein, we present a case of a 42-year-old male with chronic obstructive pulmonary disease with pulmonary infection caused by M. szulgai that was successfully treated with a regimen of rifampin, isoniazid, pyrazinamide and ethambutol for 2 months, followed by rifampin, isoniazid and azithromycin for an additional 8 months. Symptomatic and radiographic resolutions were achieved.

scholarly journals Diminished ICAM-1 Expression and Impaired Pulmonary Clearance of Nontypeable Haemophilus influenzae in a Mouse Model of Chronic Obstructive Pulmonary Disease/Emphysema

2008 ◽  
Vol 76 (11) ◽  
pp. 4959-4967 ◽  
Author(s):  
Bing Pang ◽  
Wenzhou Hong ◽  
Shayla L. West-Barnette ◽  
Nancy D. Kock ◽  
W. Edward Swords
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Haemophilus Influenzae ◽  
Pulmonary Disease ◽  
Intercellular Adhesion Molecule ◽  
Chronic Obstructive ◽  
Lung Pathology ◽  
Nontypeable Haemophilus Influenzae ◽  
Obstructive Pulmonary Disease ◽  
Pulmonary Clearance ◽  
Time Point

ABSTRACT The airways of patients with chronic obstructive pulmonary disease (COPD) are continually colonized with bacterial opportunists like nontypeable Haemophilus influenzae (NTHi), and a wealth of evidence indicates that changes in bacterial populations within the lung can influence the severity of COPD. In this study, we used a murine model for COPD/emphysema to test the hypothesis that COPD affects pulmonary clearance. Mice were treated with a pulmonary bolus of elastase, and as reported previously, the lungs of these mice were pathologically similar to those with COPD/emphysema at ∼1 month posttreatment. Pulmonary clearance of NTHi was significantly impaired in elastase-treated versus mock-treated mice. While histopathologic analysis revealed minimal differences in localized lung inflammation between the two groups, lower levels of intercellular adhesion molecule 1 (ICAM-1) were observed for the airway epithelial surface of elastase-treated mice than for those of control mice. Following infection, elastase-treated mice had lung pathology consistent with pneumonia for as long as 72 h postinfection, whereas at the same time point, mock-treated mice had cleared NTHi and showed little apparent pathology. Large aggregates of bacteria were observed within damaged lung tissue of the elastase-treated mice, whereas sparse individual bacteria were observed in lungs of mock-treated mice at the same time point postinfection. Additional infection studies showed that NTHi mutants with biofilm defects were less persistent in the elastase-treated mice than the parent strain. These findings establish a model for COPD-related infections and support the hypotheses that ICAM-1 promotes clearance of NTHi. Furthermore, the data indicate that NTHi may form biofilms within the context of COPD-related infections.

scholarly journals Association analysis between chronic obstructive pulmonary disease and polymorphisms in circadian genes

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e9806
Author(s):  
Guo Chen ◽  
Jingwei Zhang ◽  
Lijuan Zhang ◽  
Xuan Xiong ◽  
Dongke Yu ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Smoking Status ◽  
Chronic Obstructive ◽  
Lung Pathology ◽  
Nucleotide Polymorphisms ◽  
Single Nucleotide ◽  
Obstructive Pulmonary Disease ◽  
Circadian Genes ◽  
Significant Difference

Background Circadian genes have been suggested to play an important role in lung pathology. However, it remains unknown whether polymorphisms of these genes are associated with chronic obstructive pulmonary disease (COPD). Here, we aimed to investigate the association of circadian genes polymorphisms with COPD in a case-control study of 477 COPD patient and 323 control Han Chinese persons. Methods Genotyping assays were carried out for nine single nucleotide polymorphisms (SNPs) from five circadian genes (PER3, CLOCK, RORB, BMAL1 and CRY2) that were previously identified in lung pathology. Age, sex, BMI and smoking status and comorbidities were recorded for all subjects. Results No significant association was found in all SNP sites in overall subjects and no significant difference was found in age, sex, smoking status stratification analysis. Discussion The findings of this investigation indicated the effect of circadian genes polymorphisms on COPD susceptibility may only be small and possibly dependent on the subject factors, such as age and sex.

Oral and Oropharyngeal Sensory Function in Adults With Chronic Obstructive Pulmonary Disease

2020 ◽  
Vol 29 (2) ◽  
pp. 864-872
Author(s):  
Fernanda Borowsky da Rosa ◽  
Adriane Schmidt Pasqualoto ◽  
Catriona M. Steele ◽  
Renata Mancopes
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Oral Cavity ◽  
Pulmonary Disease ◽  
Thermal Sensation ◽  
Sensory Function ◽  
Control Group ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Age Related ◽  
Copd Patients

Introduction The oral cavity and pharynx have a rich sensory system composed of specialized receptors. The integrity of oropharyngeal sensation is thought to be fundamental for safe and efficient swallowing. Chronic obstructive pulmonary disease (COPD) patients are at risk for oropharyngeal sensory impairment due to frequent use of inhaled medications and comorbidities including gastroesophageal reflux disease. Objective This study aimed to describe and compare oral and oropharyngeal sensory function measured using noninstrumental clinical methods in adults with COPD and healthy controls. Method Participants included 27 adults (18 men, nine women) with a diagnosis of COPD and a mean age of 66.56 years ( SD = 8.68). The control group comprised 11 healthy adults (five men, six women) with a mean age of 60.09 years ( SD = 11.57). Spirometry measures confirmed reduced functional expiratory volumes (% predicted) in the COPD patients compared to the control participants. All participants completed a case history interview and underwent clinical evaluation of oral and oropharyngeal sensation by a speech-language pathologist. The sensory evaluation explored the detection of tactile and temperature stimuli delivered by cotton swab to six locations in the oral cavity and two in the oropharynx as well as identification of the taste of stimuli administered in 5-ml boluses to the mouth. Analyses explored the frequencies of accurate responses regarding stimulus location, temperature and taste between groups, and between age groups (“≤ 65 years” and “> 65 years”) within the COPD cohort. Results We found significantly higher frequencies of reported use of inhaled medications ( p < .001) and xerostomia ( p = .003) in the COPD cohort. Oral cavity thermal sensation ( p = .009) was reduced in the COPD participants, and a significant age-related decline in gustatory sensation was found in the COPD group ( p = .018). Conclusion This study found that most of the measures of oral and oropharyngeal sensation remained intact in the COPD group. Oral thermal sensation was impaired in individuals with COPD, and reduced gustatory sensation was observed in the older COPD participants. Possible links between these results and the use of inhaled medication by individuals with COPD are discussed.

Sign in / Sign up

Export Citation Format

Share Document